Next |
home / stock / svra / svra message board
Subject | By | Source | When |
---|---|---|---|
Impala must be doing better ... hod $2.82 | AKAPAK | investorshub | 01/26/2023 5:46:22 PM |
Wake up call to the board $2.47 | AKAPAK | investorshub | 01/25/2023 6:35:04 PM |
Finally done dumping on the new financials. | Mrfairfield | investorshub | 05/14/2021 1:57:56 PM |
Looking for comments, | 20stockman20 | investorshub | 03/23/2021 2:32:06 PM |
Wow looks like dump is still on imo | Roadtojourney | investorshub | 03/22/2021 7:23:04 PM |
Check out what BARCHART has to say about $SVRA | 20stockman20 | investorshub | 03/20/2021 5:45:44 PM |
jumped in, looks good to me | 20stockman20 | investorshub | 03/18/2021 3:11:46 PM |
Savara Inc Stock may give you a sharp | lecorb | investorshub | 03/18/2021 5:05:40 AM |
Not really, had 120 million volume yesterday | Klinsmann | investorshub | 03/17/2021 2:40:02 PM |
The volume today should say it all, surpassed | ronjon41 | investorshub | 03/17/2021 2:36:12 PM |
Looks like they still at it | maximumgriff | investorshub | 03/17/2021 12:52:51 PM |
This is one you need for long term. | Jess070283 | investorshub | 03/17/2021 12:27:54 PM |
Corrupt MM's manipulation brought it down from the | trendzone | investorshub | 03/17/2021 11:31:45 AM |
Jep, 100% agree. It traded volume of a | Klinsmann | investorshub | 03/17/2021 7:33:48 AM |
Closed a massive 130 mill Offering! Check out | maximumgriff | investorshub | 03/17/2021 12:41:13 AM |
* * $SVRA Video Chart 03-16-2021 * * | ClayTrader | investorshub | 03/16/2021 8:07:25 PM |
znewcar1: SVRA 24% v1,3M c1.97 f54,1M H2 | znewcar1 | investorshangout | 02/04/2021 11:11:31 PM |
In the money Jan. 6: Drug, burger makers | DMOST | investorshub | 01/07/2020 2:37:09 AM |
DMOST....."In Like Flint", look towards a hug | DMOST | investorshub | 01/07/2020 2:32:53 AM |
* * $SVRA Video Chart 01-02-2020 * * | ClayTrader | investorshub | 01/02/2020 10:10:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ra...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fir...
Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...